CRMD CorMedix Inc.

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on April 7-10, 2025.

24th Annual Needham Virtual Healthcare Conference

Date:Tuesday, April 8, 2025
Time:2:15p.m. EDT
Format:Fireside Chat
Webcast:
 

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: .

Investor Contact:

Dan Ferry

Managing Director

LifeSci Advisors



(617) 430-7576



EN
02/04/2025

Underlying

CRMDCorMedix Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CorMedix Inc.

 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Health...

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on April 7-10, 2025. 24th Annual Needham Virtual Healthcare Conference Date:Tuesday, April 8, 2025Time:2:15p.m. EDTFormat:Fireside ChatWeb...

April 2, 2025 1 EN
 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Resu...

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update ‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full y...

March 25, 2025 1 EN
 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Re...

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, Ma...

March 18, 2025 1 EN
 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix Announces Collaboration for DefenCath Promotion to the VA and...

CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities. This collaboration aims to enhance access ...

January 21, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 45.82
SNX TD SYNNEX CORP
WHR WHIRLPOOL CORPO... ... (+28)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols bymarket-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

SNX TD SYNNEX CORP
WHR WHIRLPOOL CORPORATION
SLAB SILICON LABORATORIES INC.
LAKE LAKELAND INDUSTRIES INC.
GTE GRAN TIERRA ENERGY
DXPE DXP ENTERPRISES INC.
COG CABOT OIL & GAS CORPORATION
AXGN AXOGEN INC.
ALLT ALLOT LTD
MEG. MEG ENERGY CORP.
PARR PAR PACIFIC HOLDINGS INC
VFC V.F. CORPORATION
CDZI CADIZ INC.
IRTC IRHYTHM TECHNOLOGIES INC.
DK DELEK US HOLDINGS INC
SWTX SPRINGWORKS THERAPEUTICS
PGNY PROGYNY
CRMD CORMEDIX INC.
LPI LAREDO PETROLEUM INC.
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
OVV OVINTIV INC
PTLO PORTILLOS INC
CIVI CIVITAS RESOURCES INC
ARHS ARHAUS INC
OPFI OPPFI INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
SN SHARKNINJA INC
ARPL ARLA PLAST AB
01/15/25 January 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch